2026-10-14T17:15:07Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34041065 2026-10-01T07:23:10Z category_37339 category_37360 category_37363 category_37375 portal_1012 item_type_6 month_year_10_2026

Supplementary Figure S1-S11 from Development of CAR T Cells Targeting a Surface RNA-Binding Protein for the Treatment of Acute Leukemias Takeshi Fujino (19772341) Jennifer Lewis (22761985) Bingyi Chen (22761997) Tamar Y. Feinberg (22939052) Maxim I. Maron (25154816) Alexander M. Lewis (25154819) Charlotte Wishnack (25154822) Quinlan Sievers (25154825) Satoshi Kaito (22547347) Winson Cai (19772305) Sarah Yoo (19772317) Serena C. Mathew (25154828) Sydney Souness (19772329) Erin Burns (22761994) Jasmine Um (22761991) Elisa de Stanchina (14954757) Qing Chang (15123489) Besnik Qeriqi (15123492) Kevin Chen (15122887) Pu Zhang (18473098) Susan DeWolf (18099749) Joshua T. Weinreb (25154831) Renata Mammone (25154834) Ileana C. Miranda (25154837) Robert F. Stanley (15123840) Maria Adriana Cuibus (25154840) Kenyon Weis (25154843) Brianna Gipson (23660801) Cynthia Castro (22761982) Nina Fox (25154846) Michael S. Lee (25154849) Jaime Alvarez-Perez (22939049) Daoqi You (15425530) Filemon S. Dela Cruz (15425512) Alyssa D. Fronk (25154852) Martin Akerman (25154855) Andrew L. Kung (15054212) Omar Abdel-Wahab (15054206) Anthony F. Daniyan (19772347) Cancer Therapeutic Research and Development Immuno-oncology Methods and Technology Biological Agents & Therapies Cell-based therapeutics Hematological Cancers Leukemias Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy Engineered/CAR T cells Preclinical Models <p>Supplementary Figure 1. Activation status of anti-U5 snRNP200 CAR T cells co-cultured with AML cells in vitro. Supplementary Figure 2. Efficacy of IL-18 armored anti-U5 snRNP200 CAR T cells and their dependency on IFNg secretion. Supplementary Figure 3. Efficacy of IL-18 armored anti-U5 snRNP200 CAR T cells in AMLPDX models. Supplementary Figure 4. Evaluation of IL-18 armored U5 snRNP200 CAR T cells in pediatric AML PDXs. Supplementary Figure 5. Safety assessment of anti-U5 snRNP200 CAR T cells. Supplementary Figure 6. Efficacy of mouse IL-18 secreting U5 snRNP200 CAR T cells in a syngeneic mouse AML model. Supplementary Figure 7. UMAPs of bone marrow cells annotated by cell type and marker gene expression in cell type. Supplementary Figure 8. Clonal expansion of endogenous T cells in mice treated with IL18 secreting anti-U5 snRNP200 CAR T cells. Supplementary Figure 9. Evaluation of mechanism underlying AML re-challenge in immunocompetent mice following AML treatment with U5 snRNP200 CAR T cells. Supplementary Figure 10. Surface expression of U5 snRNP200 and efficacy of anti-U5 snRNP200 CAR T cells in B-ALL. Supplementary Figure 11. Anti-leukemic activity of U5 snRNP200 against B-ALL in vivo.</p> 2026-10-01T00:00:00Z Text Journal contribution 10.1158/2159-8290.34041065 https://figshare.com/articles/journal_contribution/Supplementary_Figure_S1-S11_from_Development_of_CAR_T_Cells_Targeting_a_Surface_RNA-Binding_Protein_for_the_Treatment_of_Acute_Leukemias/34041065 CC BY